Related Experiment Video
Updated: Jan 1, 2026
Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
Published on: April 7, 2023
Romosozumab: a novel bone anabolic treatment option for osteoporosis?
1Department of Physical Medicine, Rehabilitation and Occupational Medicine, Medical University of Vienna, Waehringer Guertel 18-20, Vienna, 1090, Austria. Katharina.Kerschan-Schindl@meduniwien.ac.at.
Abstract:
Research into the drug romosozumab began with the investigation of patients with excess bone formation. The understanding of the wingless-type mouse mammary tumor virus integration site (Wnt) signaling pathway in bone metabolism identified the negative regulator of bone mass sclerostin as a potential target for the treatment of osteoporosis. Preclinical studies confirmed this idea because they showed that sclerostin antibodies have the potential to increase bone formation. Biochemical analyses of clinical studies showed a significant increase in bone formation markers, which then slowly decreased within a year. This was accompanied by a particularly initially pronounced decrease in bone resorption. This dual mechanism of action led to an increase in bone mineral density and a significant reduction in fracture risk. Clinical vertebral fractures decreased by between 28 and 36%, nonvertebral fractures shown in a post hoc analysis by 42%. Romosozumab is administered once a month in the form of two injections. At the puncture site, reactions occur in about 5%. The most significant side effects are cardiovascular. In phase III studies, the number of serious cardiovascular complications was not significantly, albeit numerically, higher than in the control group. In Japan, South Korea, Canada, Australia, and the USA, osteoporosis patients at a high risk of fracture may already be treated with romosozumab (Evenity). Approval in the European Union was granted by 2019-12-12.
Insights
Romosozumab, a sclerostin antibody, effectively treats osteoporosis by increasing bone formation and decreasing resorption. This dual action significantly reduces fracture risk in high-risk patients.
Area of Science:
- Endocrinology
- Bone Metabolism
- Pharmacology
Background:
- Osteoporosis is a condition characterized by low bone mass and structural deterioration.
- The wingless-type mouse mammary tumor virus integration site (Wnt) signaling pathway plays a crucial role in bone metabolism.
- Sclerostin, a negative regulator of bone mass, emerged as a therapeutic target for osteoporosis.
Purpose of the Study:
- To evaluate the efficacy and safety of romosozumab, a sclerostin antibody, in treating osteoporosis.
- To investigate the effects of romosozumab on bone formation and resorption markers.
- To assess the impact of romosozumab on bone mineral density and fracture risk reduction.
Main Methods:
- Preclinical studies utilizing sclerostin antibodies to assess bone formation potential.
- Biochemical analyses of clinical trial data to measure bone turnover markers.
- Phase III clinical trials to evaluate fracture reduction and safety profiles, including cardiovascular events.
Main Results:
- Romosozumab demonstrated a significant increase in bone formation markers, followed by a decrease.
- A pronounced initial decrease in bone resorption was observed.
- Significant reductions in clinical vertebral fractures (28-36%) and nonvertebral fractures (42%) were achieved, alongside increased bone mineral density.
- Adverse events included local injection site reactions (5%) and numerically higher, though not statistically significant, cardiovascular complications in Phase III studies.
Conclusions:
- Romosozumab exhibits a dual mechanism of action, enhancing bone formation and reducing resorption, leading to improved bone density and reduced fracture risk.
- The drug is administered monthly via injection and has received regulatory approval in several countries for high-risk osteoporosis patients.
- While generally well-tolerated, potential cardiovascular risks require consideration during treatment decisions.
More Related Videos
07:20Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
Published on: August 23, 2024
07:12Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model
Published on: September 28, 2017
Related Concept Videos
01:31Osteoclasts in Bone Remodeling
01:40Bone Remodeling
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:25Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
01:31Essential Minerals for Bone Health
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...